Scrambler疗法改善视神经脊髓炎谱系疾病疼痛:随机对照试验
结果显示Scrambler疗法组疼痛中位NRS评分从5.0降至1.5,假对照组无显著下降,且治疗组抑郁改善、治疗应答者焦虑降低,安全性相似。
要点
- Scrambler疗法可显著降低NMOSD患者的中枢性神经病理性疼痛。
- 治疗组抑郁改善,治疗应答者焦虑降低,假对照组无此变化。
- 两组安全性相似,该研究提供Class II证据。
核心结论
- Scrambler疗法是治疗NMOSD患者中枢性神经病理性疼痛有效、可行且安全的干预措施。
- Scrambler疗法减轻疼痛可能同时改善抑郁和焦虑。
研究设计与样本
- Scrambler疗法连续10个工作日,在基线、治疗结束时及30天和60天随访评估疼痛严重程度、疼痛干扰、焦虑、抑郁和睡眠障碍。
主要发现
- Scrambler疗法组中位基线NRS疼痛评分从5.0降至治疗10天后的1.5,假对照组中位NRS评分无显著下降。
- 治疗组抑郁减轻,治疗应答者亚组焦虑降低,假对照组这些症状未受影响。
- 两组安全性特征相似。
关键数值与推荐
- 中位基线NRS疼痛评分:Scrambler疗法组从5.0降至1.5(治疗10天后),假对照组无显著下降。
- 该研究提供Class II证据表明Scrambler疗法显著减轻NMOSD患者持续性中枢性神经病理性疼痛。
临床怎么用
- 对于NMOSD伴持续性中枢性神经病理性疼痛患者,可考虑使用Scrambler疗法。
- 治疗可能同时改善抑郁和焦虑症状,需关注治疗应答者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether Scrambler therapy is an effective, acceptable, and feasible treatment of persistent central neuropathic pain in patients with neuromyelitis optica spectrum disorder (NMOSD) and to explore the effect of Scrambler therapy on co-occurring symptoms. METHODS: We conducted a randomized single-blind, sham-controlled trial in patients with NMOSD who have central neuropathic pain using Scrambler therapy for 10 consecutive weekdays. Pain severity, pain interference, anxiety, depression, and sleep disturbance were assessed at baseline, at the end of treatment, and at the 30- and 60-day follow-up. RESULTS: Twenty-two patients (11 per arm) were enrolled in and completed this trial. The median baseline numeric rating scale (NRS) pain score decreased from 5.0 to 1.5 after 10 days of treatment with Scrambler therapy, whereas the median NRS score did not significantly decrease in the sham arm. Depression was also reduced in the treatment arm, and anxiety was decreased in a subset of patients who responded to treatment. These symptoms were not affected in the sham arm. The safety profiles were similar between groups. CONCLUSIONS: Scrambler therapy is an effective, feasible, and safe intervention for central neuropathic pain in patients with NMOSD. Decreasing pain with Scrambler therapy may additionally improve depression and anxiety. CLINICALTRIALSGOV IDENTIFIER: NCT03452176. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that Scrambler therapy significantly reduces pain in patients with NMOSD and persistent central neuropathic pain.
引用
- Mealy MA, Kozachik SL, Cook LJ, et al. Scrambler therapy improves pain in neuromyelitis optica: A randomized controlled trial. Neurology. 2020. PMID: 32269109. doi:10.1212/WNL.0000000000009370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。